2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
12:00 p.m. - 01:30 p.m.
MCCNO - La Nouvelle C
Technology and Procedures, Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, Immunotherapy, Adverse Events, Biological Processes, Immune Mechanism, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Research, Clinical Research, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult
PAPER

647 Description of talquetamab de-escalation practices in a real-world setting

Megan Vince, PharmD, BCOP, James A Davis, PharmD, BCOP2, Grace Elsey, PharmD3, Baylee Bryan, PharmD4, Jessica McElwee, PharmD5, Christy Khouderchah, PharmD, BCOP6, Jordan Snyder, PharmD, BCOP7, Jonathan Kissam, PharmD8, Mikhaila Rice, PharmD9, Lana Alhashimi, PharmD10, Ivan Huang, PharmD, BCOP11, Andrew J. Portuguese, MD12, Danai Dima, MD13, Rahul Banerjee, MD14, Zahra Mahmoudjafari, PharmD, BCOP15, Katelynn Granger, PharmD, BCOP16, Matthew Warrick, PharmD, BCPS, BCOP17, Shebli Atrash, MD18, Doug W. Sborov, MD, MS19, Hana Kurz, PharmD, BCOP20, Kelley Julian, PharmD, BCOP21, Donald C Moore, PharmD, BCOP22, Christopher Cahoon, PharmD23, Anthony Dominick24, Jack Khouri, MD25
1 Taussig Cancer Center, Cleveland Clinic, Cleveland, United States
2 Hollings Cancer Center, The Medical University of South Carolina, Charleston, South Carolina, United States
3 Levine Cancer Institute, Charlotte, North Carolina, United States
4 Huntsman Cancer Institute, Salt Lake City, Utah, United States
5 Levine Cancer Institute, Charlotte, North Carolina, United States
6 Fred Hutch Cancer Center, Seattle, Washington, United States
7 The University of Kansas Cancer Center, Westwood, Kansas, United States
8 Taussig Cancer Center, Cleveland Clinic, Cleveland, United States
9 Taussig Cancer Center, Cleveland Clinic, Cleveland, United States
10 Taussig Cancer Center, Cleveland Clinic, Cleveland, United States
11 Fred Hutch Cancer Center, Seattle, Washington, United States
12 Fred Hutch Cancer Center, Seattle, Washington, United States
13 Fred Hutch Cancer Center, Seattle, Washington, United States
14 Fred Hutch Cancer Center, Seattle, Washington, United States
15 The University of Kansas Cancer Center, Westwood, Kansas, United States
16 Hollings Cancer Center, The Medical University of South Carolina, Charleston, South Carolina, United States
17 Hollings Cancer Center, The Medical University of South Carolina, Charleston, South Carolina, United States
18 Levine Cancer Institute, Charlotte, North Carolina, United States
19 Huntsman Cancer Institute, Salt Lake City, Utah, United States
20 Levine Cancer Institute, Charlotte, North Carolina, United States
21 Huntsman Cancer Institute, Salt Lake City, Utah, United States
22 Levine Cancer Institute, Charlotte, North Carolina, United States
23 Huntsman Cancer Institute, Salt Lake City, Utah, United States
24 Hollings Cancer Center, The Medical University of South Carolina, Charleston, South Carolina, United States
25 Taussig Cancer Center, Cleveland Clinic, Cleveland, United States

Introduction: Talquetamab (tal) is a GPRC5D-targeted bispecific antibody (BsAb) associated with a unique side effect profile due to on-target, off tumor effects. Dosing according to the MonumenTAL-1 trial is 0.4 mg/kg weekly or 0.8 mg/kg every two weeks (Q2W) until disease progression or unacceptable toxicity; however, dose reduction or less frequent dosing can help mitigate adverse effects while maintaining response (Chari ASH 2023). Here we describe tal dose de-escalation practices in a real-world setting.

Methods: This multicenter retrospective study included patients initiated on tal at six US academic institutions prior to September 30th, 2025. Patients who received tal as pre-CAR-T bridging therapy were excluded. Dose changes from 0.4 mg/kg weekly to 0.8 mg/kg Q2W were not considered to be a de-escalation. Outcomes assessed were percentage of patients with de-escalation in tal dosing, time to de-escalation, reason for de-escalation, and re-escalation occurrence and reason. Descriptive statistics were utilized to summarize baseline demographics and outcomes. Kaplan-Meier method was used for progression free survival (PFS) and overall survival (OS) estimates.

Results: Of 227 patients included, median age was 66 (range 35-88) and 125 (55.1%) were male. The majority of patients had an ECOG of 0-2 (93.4%). Median prior lines of therapy was 6 (range 1-15) and four patients (1.8%) had prior GPRC5D exposure. Most received tal monotherapy, but 40 (17.6%) patients received tal in combination with another agent, most commonly with pomalidomide (n=26, 65%). Most patients received a target dose of 0.8 mg/kg Q2W starting at cycle 2 (n=205, 90.3%)

The majority of patients (n=166, 73.1%) maintained dosing per labeling and one patient was lost to follow up. Of the 60 patients (26.4%) who de-escalated, the most common reason was toxicity (n=32, 53.3%), followed by ongoing response (n=27, 45%), and toxicity prevention (n=13, 21.7%); for 12 patients (20%), it was a combination of those reasons. The median time from treatment initiation to first de-escalation was 4.3 (range 0.7-24.4) months.

The most common de-escalation frequency was from Q2W to Q4W (n= 51, 85%). Six patients (10%) changed from Q2W to Q3W. Of note, three patients underwent a dose de-escalation (to 0.4 mg/kg Q2W) not frequency de-escalation. Response immediately prior to de-escalation was not collected, but best response at any time during treatment of the de-escalated patients was >CR (n=27, 45%) (including unconfirmed CR), followed by VGPR (n=26, 43.3%), PR (n=5, 8.3%), and SD (n=2, 3.3%).

In patients with a de-escalation, the median duration of follow-up after first de-escalation was 12 (range 0-28.7) months. The median PFS and OS from first de-escalation was 26.9 (95% CI 6.41-NR) and 28.5 (95% CI 28.5-NR) months, respectively. Thirty-one patients (51.7%) continued tal at time of data cut off. The most common reason for discontinuation was disease progression (n=22, 75%), followed by ongoing response (n=2, 7%).

Of the patients who de-escalated, five patients underwent a second de-escalation. The leading causes were ongoing response (n=2, 40%) and toxicity prevention (n=2, 40%); for one patient, it was a combination of both. Median time from first to second de-escalation was 2 (range 0.9-15.2) months. Frequency after the second de-escalation varied from Q4W to Q6W (n=2), Q3W to Q4W (n=1), Q4W to Q12W (n=1), and 0.4 mg/kg Q2W to Q4W (n=1).

Five patients (8.3%) required re-escalation of treatment, primarily due to concern for impending progression (n=4). The median time from de-escalation to re-escalation was 3 (range 0.9-6.4) months. Four of the five patients ended up discontinuing treatment within 3 months thereafter due to progressive disease.

Conclusion: In this real-world cohort of patients on tal, reduced dosing intensity was common. Similar to the now-published results from MonumenTAL-3, patients were most often de-escalated from Q2W to Q4W dosing. Conversely, re-escalation was rare. The majority of patients who underwent de-escalation maintained responses. Future studies may assess improvement of toxicities with de-escalation and further durability of responses following de-escalation.

Megan Vince, PharmD, BCOP: No relevant conflicts of interest to declare.